Grifols (GIFLF) Cash from Operations Growth (1y) (2011 - 2020)
Powered by 
Analysis
Grifols (GIFLF) Cash from Operations Growth (1y) (2011 - 2020) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 203.97 Bn | 189.99 Bn | 7.24 Bn | 75.53% |
| 2 | Gilead Sciences | 178.74 Bn | 175.56 Bn | 6.22 Bn | 332.04% |
| 3 | Vertex Pharmaceuticals | 130.73 Bn | 122.88 Bn | 2.84 Bn | 4.87% |
| 4 | Regeneron Pharmaceuticals | 80.42 Bn | 72.42 Bn | 3.93 Bn | -28.96% |
| 5 | Argenx Se | 60.40 Bn | 55.21 Bn | 1.37 Bn | - |
| 6 | Moderna | 57.65 Bn | 52.52 Bn | 52.00 Mn | 42.76% |
| 7 | Alnylam Pharmaceuticals | 33.37 Bn | 30.07 Bn | 992.69 Mn | 151.70% |
| 8 | Biogen | 32.15 Bn | 30.86 Bn | 1.96 Bn | 178.99% |
| 9 | Roivant Sciences | 29.58 Bn | 29.58 Bn | 1.16 Mn | - |
| 10 | Grifols | 7.54 Bn | 9.09 Bn | 3.33 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2020 | 161.02% |
| Dec 31, 2019 | -19.52% |
| Mar 31, 2019 | -267.38% |
| Dec 31, 2018 | -30.55% |
| Jun 30, 2018 | -27.16% |
| Mar 31, 2018 | -26.47% |
| Dec 31, 2017 | 244.90% |
| Dec 31, 2016 | -42.75% |
| Sep 30, 2016 | 17.97% |
| Dec 31, 2015 | -15.73% |
| Sep 30, 2015 | -77.60% |
| Jun 30, 2015 | 244.34% |
| Mar 31, 2015 | -77.47% |
| Dec 31, 2014 | 31.08% |
| Sep 30, 2014 | 668.44% |
| Jun 30, 2014 | -169.60% |
| Mar 31, 2014 | 40.29% |
| Dec 31, 2013 | 49.42% |
| Sep 30, 2013 | -32.26% |
| Jun 30, 2013 | 41.71% |